A Novel, Killed-Virus Nasal Vaccinia Virus Vaccine

ABSTRACT Live-virus vaccines for smallpox are effective but have risks that are no longer acceptable for routine use in populations at minimal risk of infection. We have developed a mucosal, killed-vaccinia virus (VV) vaccine based on antimicrobial nanoemulsion (NE) of soybean oil and detergent. Incubation of VV with 10% NE for at least 60 min causes the complete disruption and inactivation of VV. Simple mixtures of NE and VV (Western Reserve serotype) (VV/NE) applied to the nares of mice resulted in both systemic and mucosal anti-VV immunity, virus-neutralizing antibodies, and Th1-biased cellular responses. Nasal vaccination with VV/NE vaccine produced protection against lethal infection equal to vaccination by scarification, with 100% survival after challenge with 77 times the 50% lethal dose of live VV. However, animals protected with VV/NE immunization did after virus challenge have clinical symptoms more extensive than animals vaccinated by scarification. VV/NE-based vaccines are highly immunogenic and induce protective mucosal and systemic immunity without the need for an inflammatory adjuvant or infection with live virus.

[1]  J. Millar,et al.  [Complications of smallpox vaccination]. , 2010, [Hokenfu zasshi] The Japanese journal for public health nurse.

[2]  Mario Roederer,et al.  Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses , 2007, The Journal of experimental medicine.

[3]  A. Phelps,et al.  Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. , 2007, Vaccine.

[4]  P. Sly,et al.  Accelerated Antigen Sampling and Transport by Airway Mucosal Dendritic Cells following Inhalation of a Bacterial Stimulus1 , 2006, The Journal of Immunology.

[5]  Andrew Pekosz,et al.  Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. , 2005, Virology.

[6]  F. Falkner,et al.  The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. , 2005, Virology.

[7]  K. Reimann,et al.  Smallpox vaccine–induced antibodies are necessary and sufficient for protection against monkeypox virus , 2005, Nature Medicine.

[8]  B. Guy,et al.  New adjuvants for parenteral and mucosal vaccines. , 2005, Therapie.

[9]  Jan Holmgren,et al.  Mucosal immunity and vaccines , 2005, Nature Medicine.

[10]  G. Poland,et al.  The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. , 2005, Vaccine.

[11]  F. Ennis,et al.  Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial , 2005, The Lancet.

[12]  M. Selgelid.  Bioterrorism and smallpox planning: information and voluntary vaccination , 2004, Journal of Medical Ethics.

[13]  Christiana N. Fogg,et al.  Protective Immunity to Vaccinia Virus Induced by Vaccination with Multiple Recombinant Outer Membrane Proteins of Intracellular and Extracellular Virions , 2004, Journal of Virology.

[14]  A. Vila,et al.  Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[15]  M. Schwehm,et al.  Smallpox: a vulnerable specter. , 2004, Epidemiology.

[16]  P. Earl,et al.  Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox , 2004, Nature.

[17]  R. Couch.  Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. , 2004, The New England journal of medicine.

[18]  Eric Gross.  Update: multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. , 2003, MMWR. Morbidity and mortality weekly report.

[19]  G. Poland,et al.  Smallpox vaccines: current and future. , 2003, The Journal of laboratory and clinical medicine.

[20]  M. Olszewski,et al.  Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. , 2003, Vaccine.

[21]  S. Hansen,et al.  Duration of antiviral immunity after smallpox vaccination , 2003, Nature Medicine.

[22]  Lihan K. Yan,et al.  Improved Assay To Detect Neutralizing Antibody following Vaccination with Diluted or Undiluted Vaccinia (Dryvax) Vaccine , 2003, Journal of Clinical Microbiology.

[23]  E. Thompson,et al.  Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates , 2003, Virology.

[24]  J. Viret,et al.  Experience with registered mucosal vaccines. , 2003, Vaccine.

[25]  Gary D. Luker,et al.  Noninvasive Bioluminescence Imaging of Herpes Simplex Virus Type 1 Infection and Therapy in Living Mice , 2002, Journal of Virology.

[26]  R. Ahmed,et al.  Recombinant Vaccinia Virus-Induced T-Cell Immunity: Quantitation of the Response to the Virus Vector and the Foreign Epitope , 2002, Journal of Virology.

[27]  N. Weiner,et al.  Topical transfection using plasmid DNA in a water-in-oil nanoemulsion. , 2001, International journal of pharmaceutics.

[28]  N. Weiner,et al.  Topical transport of hydrophilic compounds using water-in-oil nanoemulsions. , 2001, International journal of pharmaceutics.

[29]  James R. Baker,et al.  Prevention of Murine Influenza a Virus Pneumonitis by Surfactant Nano-Emulsions , 2000, Antiviral chemistry & chemotherapy.

[30]  J. Ramírez,et al.  Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine , 2000, Journal of Virology.

[31]  J. Whitton,et al.  Activated and Memory CD8+ T Cells Can Be Distinguished by Their Cytokine Profiles and Phenotypic Markers1 , 2000, The Journal of Immunology.

[32]  J. Baker,et al.  A novel surfactant nanoemulsion with broad-spectrum sporicidal activity against Bacillus species. , 1999, The Journal of infectious diseases.

[33]  R. Wittek,et al.  Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. , 1999, Virology.

[34]  R. Massung,et al.  PCR strategy for identification and differentiation of small pox and other orthopoxviruses , 1995, Journal of clinical microbiology.

[35]  B. Moss,et al.  Selection of recombinant vaccinia viruses on the basis of plaque formation. , 1995, Gene.

[36]  C. Walker,et al.  Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humans. , 1993, The Journal of general virology.

[37]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[38]  J. Baker,et al.  The fungicidal activity of novel nanoemulsion (X8W60PC) against clinically important yeast and filamentous fungi , 2004, Mycopathologia.

[39]  M. Lorenzo,et al.  Construction and isolation of recombinant vaccinia virus using genetic markers. , 2004, Methods in molecular biology.

[40]  J. Baker,et al.  A novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi. , 2001, Microbiological research.

[41]  R. Thompson,et al.  Complications of smallpox vaccination in Washington, 1968. , 1971, Northwest medicine.

[42]  V. M. Tarabrina.  [On complications in smallpox vaccination]. , 1961, Sovetskaia meditsina.